GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration

Qiang Zhou, Junxia Zhang, Qinying Cui, Xiaodong Li, Ge Gao, Yanfen Wang, Yuping Xu, Xiaoqun GaoMolecular 2015 · DOI

Abstract

Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis. The therapeutic options for malignant gliomas are limited and far from satisfactory, and novel treatment strategies are urgently required to improve the outcome of the disease. Insulin‑like growth factor (IGF)/IGF‑1 receptor (IGF‑1R) signaling pathway regulates cell proliferation, motility and survival. The dysregulation of this signaling pathway has been implicated in the development of malignant gliomas. In the present study, GSK1904529A, a small molecule inhibitor of IGF‑1R, suppressed glioma cell viability, induced glioma cell apoptosis and inhibited glioma cell migration in vitro. In addition, GSK1904529A inhibited glioma tumor growth and induced tumor cell apoptosis in vivo. In conclusion, the results of the present study suggested GSK1904529A as a promising agent for the treatment of malignant glioma.

Introduction

Malignant gliomas, particularly glioblastoma multiforme (GBM), are among the most aggressive and difficult-to-treat brain tumors. Despite standard interventions like surgery, radiation, and chemotherapy, the five-year survival rate remains a dismal 5%. The challenge lies in the tumor's ability to rapidly proliferate, resist cell death, and infiltrate healthy brain tissue.

Researchers have identified the Insulin-like Growth Factor-1 Receptor (IGF-1R) pathway as a major driver of these behaviors. When activated, IGF-1R triggers downstream signaling pathways, such as PI3K/AKT and MAPK, which promote oncogenic growth and motility. This study investigates whether GSK1904529A, a specific small-molecule inhibitor of IGF-1R, can effectively disrupt this signaling axis and suppress glioma progression.

Methodology

The researchers employed a two-tier approach to validate the drug's efficacy:

  • In Vitro Studies: Using the U87MG human glioblastoma cell line, the team measured cell viability (CellTiter-Glo assay) and migration (Transwell assays). Apoptosis was characterized using flow cytometry to analyze sub-G1 DNA content and Hoechst staining to visualize nuclear fragmentation.
  • In Vivo Studies: A xenograft model was established by injecting U87MG cells into the flanks of immunocompromised Balb/cA-nu mice. Mice were treated daily with either a vehicle control or GSK1904529A (10 or 20 mg/kg). Tumor volume and body weight were monitored, and terminal TUNEL assays were performed on resected tissue to confirm in situ apoptosis.

Key Results

GSK1904529A demonstrated high potency against glioma cells, with a half-maximal inhibitory concentration ($IC_{50}$) of approximately 50 nM. The drug exhibited a multi-pronged therapeutic effect, significantly reducing cell viability over 24–72 hours while simultaneously hindering the migratory capacity of U87MG cells.

Crucially, the treatment induced robust, dose-dependent apoptosis. Flow cytometric analysis showed a marked increase in the sub-G1 DNA population, a hallmark of programmed cell death. This was further corroborated by Hoechst staining, which revealed characteristic nuclear condensation and fragmentation in treated cells.

GSK1904529A induces dose-dependent apoptosis in U87MG glioma cells, evidenced by increased sub-G1 DNA (A), nuclear fragmentation (B), and condensed nuclei quantification (C).

In the animal model, GSK1904529A (20 mg/kg) led to a dramatic reduction in tumor volume by day 11 compared to controls. TUNEL staining of resected tumors confirmed a high density of apoptotic cells within the tumor mass, indicating that the drug's mechanism of action translates effectively to a living system. Notably, the treatment was well-tolerated, with no significant weight loss observed in the mice.

Discussion and Future Directions

The findings suggest that GSK1904529A is a promising candidate for glioma therapy due to its ability to inhibit growth, induce death, and prevent migration. However, several challenges remain. Because this study used a subcutaneous xenograft model, the drug's ability to penetrate the blood-brain barrier (BBB) remains unverified.

Future research should utilize orthotopic models (implanting tumors directly into the brain) to better simulate the clinical environment and evaluate BBB penetration. Additionally, exploring combination therapies with existing chemotherapeutic agents may help mitigate potential drug resistance and enhance overall clinical outcomes.

Summary updated

Abstract

Malignant gliomas are the most common type of primary malignancy of the central nervous system, with a poor prognosis. The therapeutic options for malignant gliomas are limited and far from satisfactory, and novel treatment strategies are urgently required to improve the outcome of the disease. Insulin‑like growth factor (IGF)/IGF‑1 receptor (IGF‑1R) signaling pathway regulates cell proliferation, motility and survival. The dysregulation of this signaling pathway has been implicated in the development of malignant gliomas. In the present study, GSK1904529A, a small molecule inhibitor of IGF‑1R, suppressed glioma cell viability, induced glioma cell apoptosis and inhibited glioma cell migration in vitro. In addition, GSK1904529A inhibited glioma tumor growth and induced tumor cell apoptosis in vivo. In conclusion, the results of the present study suggested GSK1904529A as a promising agent for the treatment of malignant glioma.
BibTeX
@inproceedings{zhou2015gsk,
  author = {Qiang Zhou and Junxia Zhang and QINYING CUI and Xiaodong Li and Ge Gao and Yanfen Wang and Yuping Xu and Xiaoqun Gao},
  title = {{GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.3892/mmr.2015.3869},
}
Figure